Regeneron Pharmaceuticals Stock News

LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws.

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt - EVP, Commercial Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone. Thanks so much for joining us.

Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears. Regeneron's 40% drop is driven by multiple factors, including Eylea's market share concerns, DOJ lawsuits, and general sector uneasiness. Despite the drop, Regeneron remains a highly profitable company with a robus...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regener...

Their recent issues are nothing to fret over for investors focused on the long game.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria